OC Business Journal

CathWorks FFRangio® System: A New Era in Coronary Physiology

– Ramin Mousavi, President and Chief Executive Officer

CathWorks, based in Kfar Saba, Israel and Irvine, CA, is a fast-paced medical device start-up focused on digital health innovations to improve the lives of patients globally. Fractional flow reserve (FFR) is a diagnostic technique that evaluates the physiologic impact of coronary artery stenosis, making it an important decisionmaking tool when managing patients with coronary artery disease (CAD). While FFR is an important diagnostic tool backed by strong clinical evidence, the nature of traditional FFR — which requires invasive pressure wires and drug stimulation — has resulted in its underutilization around the globe.

Unlike traditional FFR, the CathWorks FFRangio® System eliminates the invasive and cumbersome nature of traditional wire-based physiology. Instead, the FFRangio technology combines artificial intelligence (AI) and advanced computational science to obtain physiologic information from routine angiograms (X-rays). It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree, enabling them to make better treatment decisions for their patients.

Recently, CathWorks entered into a strategic partnership with Medtronic to market and sell the CathWorks FFRangio® System globally. Medtronic is the global leader in medical technology and has more than 90,000 employees worldwide in more than 150 countries. The partnership with Medtronic will expand CathWorks’ footprint globally, enabling more patients to benefit from its revolutionary technology that is poised to disrupt the current coronary physiology market.

“CathWorks has been looking for the right partner to help us expand the reach of the FFRangio System globally to truly transform how cardiovascular disease is diagnosed and treated. Medtronic not only brings the strength of its commercial team to CathWorks, but a reputation of investing and defining new opportunities to revolutionize care. I am excited about the possibilities ahead as we partner with Medtronic to bring our technology to more physicians and patients in the U.S., Japan and Europe.”

HEALTHCARE

en-us

2022-08-08T07:00:00.0000000Z

2022-08-08T07:00:00.0000000Z

https://ocbusinessjournal.pressreader.com/article/281990381288963

LABJ